Pregnancy and breastfeeding in patients with Crohn's disease

Details

Serval ID
serval:BIB_3A1A2654D5CE
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Pregnancy and breastfeeding in patients with Crohn's disease
Journal
Digestion
Author(s)
Mottet Christian, Juillerat Pascal, Pittet Valérie, Gonvers Jean-Jacques, Froehlich Florian, Vader John-Paul, Michetti Pierre, Felley Christian
ISSN
0012-2823
Publication state
Published
Issued date
2007
Peer-reviewed
Oui
Volume
76
Number
2
Pages
149-160
Language
english
Abstract
Crohn's disease commonly affects women of childbearing age. Available data on Crohn's disease and pregnancy show that women with Crohn's disease can expect to conceive successfully, carry to term and deliver a healthy baby. Control of disease activity before conception and during pregnancy is critical, to optimize both maternal and fetal health. Generally speaking, pharmacological therapy for Crohn's disease during pregnancy is similar to pharmacological therapy for nonpregnant patients. Patients maintained in remission by way of pharmacological therapy should continue it throughout their pregnancy. Sulfasalazine, mesalazine and corticosteroids are safe, azathioprine and 6-mercaptopurine are reasonably safe with few discordant data, infliximab seems safe as well, whereas methotrexate is contraindicated during pregnancy. During breastfeeding, mesalazine and prednisone are considered safe, azathioprine/6-mercaptopurine, budesonide and infliximab probably safe and methotrexate is contraindicated. [Ed.]
Keywords
Anti-Infective Agents, Anti-Infective Agents/therapeutic use, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Breast Feeding, Crohn Disease, Crohn Disease/drug therapy, Drug Therapy, Combination, Female, Glucocorticoids, Glucocorticoids/therapeutic use, Humans, Immunologic Factors/therapeutic use, Mesalamine, Pregnancy, Pregnancy Complications, Pregnancy Complications/drug therapy, Pregnancy Outcome, Safety
Pubmed
Web of science
Create date
03/03/2008 10:52
Last modification date
20/08/2019 13:29
Usage data